Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
Head of Machine Learning, Lucas Camillo, to lead team with Professor Bo Wang, University of Toronto, appointed as Senior Advisor Expansion into global AI hub to accelerate growth of IP portfolio and ...
Nanosecond PFA Cardiac Surgical System for ablation of cardiac tissue to be highlighted in presentation and poster sessions. “We believe the Nanosecond PFA Cardiac Surgical System has the potential to ...
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA ...
SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has achieved technological proof of concept for ...
Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family Next-generation vaccine ...
KELOWNA, BC / ACCESS Newswire / April 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the ...
Dallas-based Colossal says it is one step closer to bringing back the woolly mammoth. Colossal Biosciences announced Tuesday that it had created the Colossal woolly mouse, genetically engineered mice ...
Clinical Trials Arena on MSN
SK bioscience begins international phase I/II trial for GBP511 vaccine
The Phase I/II study will enrol approximately 368 adults aged 18 years and above.
Arterra Bioscience SpA ( (IT:ARBS)) has issued an announcement. Arterra Bioscience S.p.A. reported a significant revenue increase of 29% as of September 30, 2025, reaching approximately 3.6 million ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results